Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma

Priyanka A. Pophali, Gita Thanarajasingam

Research output: Contribution to journalReview articlepeer-review


Mantle cell lymphoma (MCL) is a unique lymphoma that is heterogeneous in its clinical course, and lacks consensus treatment approaches. It is often treated with immunochemotherapy at diagnosis and chronic therapies in relapse. Despite significant advances in therapy, MCL remains incurable. Maintaining patients’ health-related quality of life (HRQOL) is an important treatment goal. Assessment of HRQOL elucidates the impact of an illness and its treatment on patients’ lives. This review highlights the relevance of HRQOL assessment in MCL, evaluates existing evidence, current knowledge gaps and challenges in HRQOL assessment, and defines future directions for improving HRQOL evaluation in MCL patients.

Original languageEnglish (US)
Pages (from-to)971-982
Number of pages12
JournalHematology/Oncology Clinics of North America
Issue number5
StatePublished - Oct 2020


  • Adverse events
  • Chronic therapy
  • Mantle cell lymphoma
  • Patient-reported outcomes
  • Toxicity

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma'. Together they form a unique fingerprint.

Cite this